Tb guidelins
Reading File
Finding Sources
Searching PubMed
"tuberculosis"[MeSH Terms] AND "treatment guidelines"
Searching the Web
WHO tuberculosis treatment guidelines 2025 2026
Finding Sources
Reading Web Page
tuberculosis treatment guidelines 2025
Finding Sources
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive summary of current TB treatment guidelines, incorporating the latest 2024–2025 updates from WHO, ATS/CDC/ERS/IDSA, and standard textbook recommendations.
Tuberculosis (TB) Treatment Guidelines
1. Latent TB Infection (LTBI)
Goal: prevent progression to active disease. Preferred regimens (Goldman-Cecil Medicine):
| Regimen | Duration | Dosing |
|---|---|---|
| Isoniazid (H) + Rifapentine (P) | 3 months | Once weekly |
| Rifampin (R) alone | 4 months | Daily |
| Isoniazid + Rifampin | 3 months | Daily |
| Isoniazid alone | 6 months | Daily |
| Isoniazid alone | 9 months | Daily |
Pyridoxine (Vitamin B6) 25–50 mg/day should be co-administered with isoniazid in all patients at risk of neuropathy (elderly, pregnant, malnourished, diabetic, HIV+, alcohol use).
2. Drug-Susceptible TB (DS-TB) — Active Disease
Standard 6-Month Regimen (Classic)
- Intensive phase (2 months): Isoniazid (H) + Rifampin (R) + Pyrazinamide (Z) + Ethambutol (E) — HRZE
- Continuation phase (4 months): Isoniazid + Rifampin — HR
This is the preferred regimen for newly diagnosed pulmonary TB.
🆕 NEW 4-Month Regimen (ATS/CDC/ERS/IDSA, December 2024)
The updated ATS/CDC/ERS/IDSA guideline (published Dec 31, 2024) now recommends:
- Adults & adolescents ≥12 years: 2HPZM / 2HPM
- 2 months of Isoniazid + Rifapentine + Pyrazinamide + Moxifloxacin, then
- 2 months of Isoniazid + Rifapentine + Moxifloxacin
- Children 3 months–16 years (non-severe TB): 2HRZE / 2HR (4 months total)
3. Drug-Resistant TB
MDR-TB / RR-TB (Resistant to Isoniazid + Rifampin)
🆕 WHO Consolidated Guidelines, Module 4 (April 2025) introduced a landmark update:
BDLLfxC Regimen (NEW, 6 months, all-oral)
- Bedaquiline + Delamanid + Linezolid + Levofloxacin + Clofazimine
- Recommended for MDR/RR-TB with or without additional fluoroquinolone resistance (pre-XDR-TB)
- Replaces longer regimens previously lasting 9–20 months
BPaLM Regimen (Established, 6 months)
- Bedaquiline + Pretomanid + Linezolid + Moxifloxacin
- Validated in TB PRACTECAL trial — noninferior to standard care with fewer serious adverse events
- WHO-recommended since 2022 guidelines update
BPaL Regimen (XDR-TB / treatment-intolerant)
- Bedaquiline + Pretomanid + Linezolid (Nix-TB study)
- 90% favorable outcomes in XDR-TB
- Higher adverse events (mainly linezolid toxicity)
Modified 9-Month Regimen
- Still recommended where fluoroquinolone resistance is excluded
- Used in settings where newer drugs are unavailable
Key shift: Kanamycin and capreomycin are no longer recommended due to increased toxicity and worse outcomes (per individual patient-level meta-analysis).
Pre-XDR-TB and XDR-TB
Defined as MDR/RR-TB + resistance to any fluoroquinolone (pre-XDR) or additional resistance to bedaquiline/linezolid (XDR). Managed with BPaLM or BPaLM-variant regimens under specialist supervision.
4. Special Populations
| Population | Consideration |
|---|---|
| HIV co-infection | Start ART within 2 weeks of TB treatment; same duration as HIV-negative; similar sputum conversion rates |
| TB meningitis | Add corticosteroids (dexamethasone); mortality ~25% (HIV+: ~50%) even with treatment |
| Pregnancy | Avoid pyrazinamide in some guidelines; rifampin is safe; isoniazid + pyridoxine |
| Children | Weight-based dosing; non-severe disease may qualify for 4-month regimen |
| Renal impairment | Reduce aminoglycoside doses; avoid kanamycin/capreomycin |
5. Directly Observed Therapy (DOT)
DOT remains the standard of care — a healthcare worker observes ingestion of medication, particularly for twice-weekly regimens and MDR-TB treatment.
6. Monitoring & Outcomes
- After 2 weeks of effective treatment: 99.9% decline in bacterial colony counts; patient becomes non-infectious
- Drug-susceptible TB cure rate: ~100% with completed treatment
- MDR-TB cure rate: 50–60%
- XDR-TB cure rate: 2–22% (improving with new regimens; BPaLM achieving ~90%)
- Global treatment success: 85%; US: 95%
Summary of Key 2024–2025 Changes
| Update | Source | Change |
|---|---|---|
| 4-month regimen for DS-TB | ATS/CDC/ERS/IDSA (Dec 2024) | 2HPZM/2HPM replaces 6-month for eligible adults |
| BDLLfxC for MDR/RR-TB | WHO Module 4 (Apr 2025) | New all-oral 6-month regimen, even for pre-XDR |
| TB + undernutrition | WHO Module 6 (Oct 2025) | Food assistance for household contacts in food-insecure settings |
| AI screening | 2026 guidelines | AI chest X-ray reading with sensitivity exceeding human experts; "X-ray for any cough" |
Sources: Harrison's Principles of Internal Medicine 22E (2025); Goldman-Cecil Medicine; ATS/CDC/ERS/IDSA Clinical Practice Guideline (Dec 2024); WHO Consolidated Guidelines on TB, Module 4 (Apr 2025); WHO Module 6 (Oct 2025)
This is a shared conversation. Sign in to Orris to start your own chat.